GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma A/S (NAS:ASND) » Definitions » Cyclically Adjusted PB Ratio

Ascendis Pharma A/S (Ascendis Pharma A/S) Cyclically Adjusted PB Ratio : 13.38 (As of May. 26, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Ascendis Pharma A/S Cyclically Adjusted PB Ratio?

As of today (2024-05-26), Ascendis Pharma A/S's current share price is $130.41. Ascendis Pharma A/S's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $9.75. Ascendis Pharma A/S's Cyclically Adjusted PB Ratio for today is 13.38.

The historical rank and industry rank for Ascendis Pharma A/S's Cyclically Adjusted PB Ratio or its related term are showing as below:

ASND' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 6.71   Med: 9.42   Max: 15.97
Current: 13.37

During the past years, Ascendis Pharma A/S's highest Cyclically Adjusted PB Ratio was 15.97. The lowest was 6.71. And the median was 9.42.

ASND's Cyclically Adjusted PB Ratio is ranked worse than
94.03% of 653 companies
in the Biotechnology industry
Industry Median: 1.73 vs ASND: 13.37

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Ascendis Pharma A/S's adjusted book value per share data for the three months ended in Mar. 2024 was $-4.533. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $9.75 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Ascendis Pharma A/S Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Ascendis Pharma A/S's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascendis Pharma A/S Cyclically Adjusted PB Ratio Chart

Ascendis Pharma A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 12.62

Ascendis Pharma A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.29 8.61 9.23 12.62 15.50

Competitive Comparison of Ascendis Pharma A/S's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Ascendis Pharma A/S's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma A/S's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma A/S's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma A/S's Cyclically Adjusted PB Ratio falls into.



Ascendis Pharma A/S Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Ascendis Pharma A/S's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=130.41/9.75
=13.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma A/S's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Ascendis Pharma A/S's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-4.533/118.4000*118.4000
=-4.533

Current CPI (Mar. 2024) = 118.4000.

Ascendis Pharma A/S Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.000 99.700 0.000
201409 0.190 99.700 0.226
201412 3.335 99.400 3.972
201503 6.774 100.200 8.004
201506 6.296 100.300 7.432
201509 5.883 100.200 6.952
201512 5.216 99.800 6.188
201603 4.516 100.200 5.336
201606 4.065 100.600 4.784
201609 3.312 100.200 3.914
201612 5.746 100.300 6.783
201703 5.095 101.200 5.961
201706 4.372 101.200 5.115
201709 6.625 101.800 7.705
201712 5.990 101.300 7.001
201803 10.316 101.700 12.010
201806 9.276 102.300 10.736
201809 8.445 102.400 9.765
201812 7.561 102.100 8.768
201903 17.256 102.900 19.855
201906 16.044 102.900 18.461
201909 15.247 102.900 17.544
201912 13.826 102.900 15.909
202003 12.638 103.300 14.485
202006 11.114 103.200 12.751
202009 20.983 103.500 24.004
202012 18.983 103.400 21.737
202103 17.755 104.300 20.155
202106 15.367 105.000 17.328
202109 20.551 105.800 22.998
202112 17.536 106.600 19.477
202203 13.278 109.900 14.305
202206 11.513 113.600 11.999
202209 7.840 116.400 7.975
202212 4.881 115.900 4.986
202303 3.184 117.300 3.214
202306 1.250 116.400 1.271
202309 -1.386 117.400 -1.398
202312 -2.806 116.700 -2.847
202403 -4.533 118.400 -4.533

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ascendis Pharma A/S  (NAS:ASND) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Ascendis Pharma A/S Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Ascendis Pharma A/S's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascendis Pharma A/S (Ascendis Pharma A/S) Business Description

Traded in Other Exchanges
Address
Tuborg Boulevard 12, Hellerup, DNK, DK-2900
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.

Ascendis Pharma A/S (Ascendis Pharma A/S) Headlines

From GuruFocus

Ascendis Pharma to Host Oncology Program Update on May 31

By sperokesalga sperokesalga 05-25-2023